Trial
NCT03742973
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Primary Biliary Cholangitis
Intervention
Baricitinib
Why stopped
Study was terminated due to enrollment futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-14